Oxford University resumes vaccine trial

Oxford University resumes vaccine trial

The company said it could not disclose further medical information.

An independent committee was drafted in to review safety, in what the company and the World Health Organization described as a routine step.

Dr. Soumya Swaminathan, the World Health Organization's chief scientist, said the United Nations health agency wasn't overly concerned by the pause in the Oxford and AstraZeneca vaccine trial, describing it as "a wake-up call" to the global community about the inevitable ups and downs of medical research.

"Clinical trial's postponement (by AstraZeneca) puts into question some pharma companies' request for full indemnification from any risks from their vaccines by purchasing nations".

Though it would not disclose information about the patient's illness for reasons of participant confidentiality, an AstraZeneca spokesman said earlier this week that a woman had developed severe neurological symptoms that prompted the pause in testing.

On Thursday, the Serum Institute, headed by Adar Poonawalla, said it would pause Phase 3 trials that were to begin in India next week after AstraZeneca stopped vaccine trials across four nations as a precautionary measure.

The pharma giant also stated that it had "voluntarily paused" the trial.

It said: "The independent review process has concluded and following the recommendations of both the independent safety review committee and the United Kingdom regulator, the MHRA, the trials will recommence in the UK".

Lampard says Havertz will be given time to blossom in Chelsea
Mark Lawrenson is backing Chelsea FC to ease to a straightforward win against Brighton at the Amex Stadium on Monday night. I wasn't able to bring in players I felt might be helpful for the way I wanted to go and the style I wanted to play.

"AstraZeneca is committed to the safety of trial participants and the highest standards of conduct in clinical trials", Saturday's statement read.

But Dr Smith said the condition is not only linked to vaccination and it can also happen by chance to some people.

It uses a weakened version of a common cold-causing adenovirus engineered to code for the spike protein that COVID-19 uses to invade cells.

Swaminathan says early data in human vaccine candidates so far has been "quite promising", showing the shots trigger an immune response.

The Oxford university vaccine trial has resumed.

Phase three is concerned with testing the efficacy and safety of a vaccine before it is licensed and it usually involves several thousands of volunteers.

"Globally some 18,000 individuals have received study vaccines as part of the trial". Sites outside the U.S., including in Chile and Peru, are due to begin recruitment shortly.

"The Company will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic", the spokesperson, Michele Meixell, wrote in an email.

Related Articles